Maravai LifeSciences Holdings Inc - 2026年季度报告

For the quarterly period ended March31, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. TABLE OF CONTENTS Forward-Looking Statements PART I - FINANCIAL INFORMATION Item 1. Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 20255Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025(unaudited)6Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and7 PART II - OTHER INFORMATION Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the U.S. Private SecuritiesLitigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including, withoutlimitation, statements under the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financialcondition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements bythe fact that they do not relate strictly to historical or current facts. These statements often may include words such as “anticipate,” •The level of our customers’ spending on and demand for TriLink and Cygnus products and services.•Our operating results are prone to significant fluctuation, which may make our future operating results difficult to predict andcould cause our actual operating results to fall below expectations or any guidance we may provide.•Uncertainty regarding the extent and duration of our revenue associated with high-volume sales of CleanCap® forcommercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside ourcontrol.•Shifts in the trade, economic and other policies and priorities of the U.S. federal government, on our and our customers’current and future business operations.•Unintended consequences from our recent organizational changes and workforce reduction.•Use of our products by customers in the production of vaccines and therapies, some of which represent relatively new andstill-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development ofalternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on our customers’use of our products and services.•Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than us andpotentially capable of developing new approaches that could make our products, services and technology obsolete.•The potential failure of our products and services to perform as expected and the reliability of the technology on which ourproducts and services are based.•Our use of Artificial Intelligence technologies, including Machine Learning, and business, compliance, and reputationalchallenges that may result from such use.•The risk that our products do not comply with required quality standards.•Market acceptance of our life science reagents.•Our ability to efficiently manage our strategic acquisitions and organic growth opportunities.•Natural disasters, geopolitical instability (including ongoing military conflicts) and other catastrophic events. •Our existing level of indebtedness